SAFETY AND EFFICACY OF PEGYLATED INTERFERON ALFA-2A FOR THE TREATMENT OF HEPATITIS C IN PATIENTS WITH MAJOR THALASSEMIA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ALAVIAN SEYED MOAYED; ABOU ALGHASEMI HASAN; MIRI SEYED MOHAMMAD; KESHVARI MARYAM; KARIMI ELIZI PEGAH; BEHNAVA BITA; TABATABAEI SEYED VAHID; HAJI BEYGI BASHIR; BAGHERI LANKARANI KAMRAN

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Blood and Cancer Year:2009 | Volume:1 | Issue:4 Page(s): 129-137

Download Full-Text

View:

284

Download:

Cites:

Information Journal Paper

Title

SAFETY AND EFFICACY OF PEGYLATED INTERFERON ALFA-2A FOR THE TREATMENT OF HEPATITIS C IN PATIENTS WITH MAJOR THALASSEMIA

Author(s)

Keywords

CHRONIC HEPATITIS C

THALASSEMIA

PEGINTERFERON ALFA-2A

Abstract

Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients.Materials and Methods: A cohort of 51 HCV-RNA positive thalassemic patients was enrolled to our study and received 180 mg PEG-IFN A-2a once-weekly for 48 weeks. The primary end point was sustained virological response (SVR). The secondary outcome was normalization of ALT. Patient safety was assured by monthly, and if needed, weekly laboratory assessment and visits.Results: Of 52 patients, 42 participants completed the treatment schedule. A sustained virological response (SVR) was attained in 22/51 (43%) cases. Among non-responders or relapsers to previous HCV antiviral therapy, 9/27 (33%) attained an SVR. Five patients died during treatment and 3 subjects discontinued the therapy because of adverse effects. Adverse events were generally mild, and laboratory abnormalities were rare.Conclusion: A course of 48-week PEG-IFN A-2a monotherapy is effective in eradicating HCV-RNA during treatment. But about one third of thalassemic patients would relapse within 6 months of treatment schedule completion, in whom combination therapy is needed.

Cites

No record.

References

No record.

Cite

APA: Copy

ALAVIAN, SEYED MOAYED, ABOU ALGHASEMI, HASAN, MIRI, SEYED MOHAMMAD, KESHVARI, MARYAM, KARIMI ELIZI, PEGAH, BEHNAVA, BITA, TABATABAEI, SEYED VAHID, HAJI BEYGI, BASHIR, & BAGHERI LANKARANI, KAMRAN. (2009). SAFETY AND EFFICACY OF PEGYLATED INTERFERON ALFA-2A FOR THE TREATMENT OF HEPATITIS C IN PATIENTS WITH MAJOR THALASSEMIA. IRANIAN JOURNAL OF BLOOD AND CANCER (IJBC), 1(4), 129-137. SID. https://sid.ir/paper/313136/en

Vancouver: Copy

ALAVIAN SEYED MOAYED, ABOU ALGHASEMI HASAN, MIRI SEYED MOHAMMAD, KESHVARI MARYAM, KARIMI ELIZI PEGAH, BEHNAVA BITA, TABATABAEI SEYED VAHID, HAJI BEYGI BASHIR, BAGHERI LANKARANI KAMRAN. SAFETY AND EFFICACY OF PEGYLATED INTERFERON ALFA-2A FOR THE TREATMENT OF HEPATITIS C IN PATIENTS WITH MAJOR THALASSEMIA. IRANIAN JOURNAL OF BLOOD AND CANCER (IJBC)[Internet]. 2009;1(4):129-137. Available from: https://sid.ir/paper/313136/en

IEEE: Copy

SEYED MOAYED ALAVIAN, HASAN ABOU ALGHASEMI, SEYED MOHAMMAD MIRI, MARYAM KESHVARI, PEGAH KARIMI ELIZI, BITA BEHNAVA, SEYED VAHID TABATABAEI, BASHIR HAJI BEYGI, and KAMRAN BAGHERI LANKARANI, “SAFETY AND EFFICACY OF PEGYLATED INTERFERON ALFA-2A FOR THE TREATMENT OF HEPATITIS C IN PATIENTS WITH MAJOR THALASSEMIA,” IRANIAN JOURNAL OF BLOOD AND CANCER (IJBC), vol. 1, no. 4, pp. 129–137, 2009, [Online]. Available: https://sid.ir/paper/313136/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops